Federated Hermes Inc. Purchases Shares of 40,629 Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Key Points

• Federated Hermes Inc. has acquired a new position in Integra LifeSciences, buying 40,629 shares valued at approximately $893,000 during the first quarter, representing 0.05% of the company's stock.
• Institutional investors currently hold 84.78% of Integra LifeSciences, with significant recent increases in holdings from several firms including Quadrant Capital Group and Sterling Capital Management.
• After reporting better-than-expected quarterly earnings, the stock's target prices were revised downwards by multiple analysts, with various ratings ranging from sell to hold and an average target price of $18.63.

Federated Hermes Inc. purchased a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 40,629 shares of the life sciences company's stock, valued at approximately $893,000. Federated Hermes Inc. owned about 0.05% of Integra LifeSciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of IART. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Integra LifeSciences by 16.3% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,811 shares of the life sciences company's stock valued at $370,000 after purchasing an additional 2,357 shares in the last quarter. Allianz Asset Management GmbH raised its position in Integra LifeSciences by 92.6% during the 1st quarter. Allianz Asset Management GmbH now owns 149,614 shares of the life sciences company's stock valued at $3,290,000 after purchasing an additional 71,939 shares in the last quarter. Victory Capital Management Inc. raised its position in Integra LifeSciences by 1,067.6% during the 1st quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company's stock valued at $3,254,000 after purchasing an additional 135,308 shares in the last quarter. CWM LLC raised its position in Integra LifeSciences by 413.8% during the 1st quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock valued at $147,000 after purchasing an additional 5,367 shares in the last quarter. Finally, Arizona State Retirement System raised its position in Integra LifeSciences by 4.2% during the 1st quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company's stock valued at $437,000 after purchasing an additional 795 shares in the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Up 8.9%

IART stock traded up $1.14 on Tuesday, hitting $13.89. 361,085 shares of the company's stock were exchanged, compared to its average volume of 1,015,602. Integra LifeSciences Holdings Corporation has a 12-month low of $11.06 and a 12-month high of $27.13. The firm has a 50 day moving average price of $12.60 and a two-hundred day moving average price of $17.08. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The stock has a market cap of $1.08 billion, a P/E ratio of -2.12, a price-to-earnings-growth ratio of 0.73 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%. The firm had revenue of $415.61 million for the quarter, compared to the consensus estimate of $395.06 million. During the same period in the previous year, the business earned $0.63 EPS. The firm's revenue for the quarter was down .6% on a year-over-year basis. As a group, equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. cut their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. JMP Securities cut their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Finally, Wells Fargo & Company cut their price target on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.